Objective To determine the predictors of the therapeutic effects of tocilizumab (TCZ) switched from other biologics with different mechanisms of action in rheumatoid arthritis (RA).
Introduction
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by joint pain and swelling, and eventual progression to joint destruction. By the end of the 20th century, the use of anti-tumor necrosis factor inhibitors (TNFis) raised treatment standards for RA by achieving impressive symptomatic relief, significant improvement in quality of life, and substantially increased work time 1, 2) , as well as prevent-ing the progression of joint destruction 3) . Currently, non-TNFis (tocilizumab [TCZ] and abatacept [ABT]) are also available. In addition, the existence of therapeutic windows of opportunity and the concept of "treat-to-target" have become widely accepted, and clinical remission and/or low RA disease activity are achievable goals. In general, TNFis are effective in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), including methotrexate (MTX). How-ever, TNFis are inadequate or ineffective in approximately 30% of patients, with two-thirds exhibiting moderate to high disease activity at 1 year post-treatment 4) . A previous report that studied 3497 patients who discontinued first-line TNFis showed that 73.3% were switched to another TNFis and 26.7% were switched to a non-TNFis 5) . According to the recommendations from the European League Against Rheumatism, patients who do not respond to initial TNFi therapy should be switched to a different TNFi or to a different class of biological agents 6) .
The ability to predict whether patients will respond to their current treatment, particularly in the early phase, is important to help decide whether to continue with the treatment. Some predictors of DMARD treatments have been proposed. Low disease activity at baseline was reported to be associated with clinical remission in RA patients treated with TNFis 7, 8) . In 214 patients treated with ABT, multivariate logistic regression demonstrated that high disease activity at baseline was an independent predictor for achieving low disease activity at 24 weeks 3) . Another study examined the baseline serum ratio of the type I collagen C-terminal telopeptide to osteocalcin. This ratio reflects bone turnover and serum matrix metalloproteinase-derived fragments of type I, II, and III collagen levels and was found to be a biomarker for predicting TCZ responders 9) .
As described above, repots have documented several clinically available biomarkers or predictors of success after switching biologics. However, there is currently no consensus on what strategy to adopt when switching biologics, particularly when switching from one non-TNFi to another.
According to a large Japanese RA database, the National Database of Rheumatic Disease in Japan (NinJa), the age at RA onset has increased significantly over the last decade 10) . The incidence of adverse side effects of ABT therapy was thought to be relativity low, so ABT was preferentially used in elderly patients and/or in patients with comorbidities. It is not always possible to use an adequate dose of MTX in elderly patients because of their reduced physical function. MTX use is also even occasionally contraindicated in young patients due to comorbidities associated with ABT. Hence, biologics that provide an adequate therapeutic response without the need for concomitant MTX would be appropriate treatment for some patients switching from ABT. The anti-IL-6 receptor antibody TCZ achieves a good therapeutic response in RA patients without concomi-tant MTX administration. Hence, TCZ considered to be suitable option for continuing treatment when switching from ABT. However, the efficacy of switching to TCZ from ABT is unknown, and predictors of this efficacy have not been identified. Furthermore, the rate of adverse events (AEs) during TCZ therapy is thought to be slightly higher than during ABT therapy [11] [12] [13] [14] , and the appropriateness of switching from ABT to TCZ in terms of potential AEs is unknown. In this study, we examined the effectiveness and safety of switching from the non-TNFi ABT to TCZ, compared with switching from a TNFi to TCZ.
Patients and Methods

Patients
This study was approved by the St. Marianna University School of Medicine ethics committee (Approval No. 4509). Eligible patients had been diagnosed with RA according to the 2010 American College of Rheumatology-/-European League Against Rheumatism classification criteria 15) , were taking biological agents after being switched from biological DMARDs other than TCZ, and had a 28-joint disease activity score with erythrocyte sedimentation rate (3) (DAS28-ESR (3)) that could be calculated at baseline and at week 24 after starting TCZ therapy. Data were retrospectively collected from clinical records from September 2008 to April 2018 at St. Marianna University School of Medicine hospital in Japan.
Study design
To detect the predictors of low disease activity, we compared the baseline characteristics between patients treated with ABT vs. TNFis. To identify predictors in the early period, we analyzed the difference in DAS28-ESR (3) scores from the initiation of TCZ therapy (ΔDAS) to week 4. Finally, ΔDAS was compared according to the previous therapy (ABT or TNFis).
In this study, clinical disease activity was evaluated using the DAS28-ESR 
Safety assessment
Another objective of this study was to assess the safety of TCZ when patients were switched from other biologics with different mechanisms of action. To evaluate safety, we retrospectively recorded the incidence of AEs.
Statistical analysis
Demographic and disease characteristics were reported using descriptive statistics. Predictors of low disease activity were verified using regression analysis and receiver operating characteristic (ROC) analysis. The following data were recorded at the initiation of TCZ therapy (baseline, week 0): sex, age, disease duration, rheumatoid factor (RF) titer, anti-cyclic citrullinated peptide antibody titer, matrix metalloproteinase-3 level, concomitant treatment (MTX or prednisolone), and the number of biologics used in the past. The following disease parameters were recorded at baseline and after 24 weeks of TCZ treatment: number of tender and swollen joints (tender and swollen joint counts) among 28 joints, erythrocyte sedimentation rate (ESR), serum c-reactive protein levels, and DAS28-ESR (3). All results are expressed as mean ± standard deviation or percentage. The Student's t-test or the Mann-Whitney t-test were used for two-group comparisons. All statistical tests were twosided, and the level of significance was defined as p < 0.05. All analyses were performed using SPSS version 25.0.0 software (IBM Corp., Armonk, NY, USA).
Results
Patient enrollment and baseline demographics
Sixty-seven patients were enrolled in this study. Patients' baseline characteristics when they switched from TNFis or ABT to TCZ are shown in Tables 1, 2, and 3. In the overall sample, the mean age was 56.8 ± 15.5 years, most patients were women (85.1%), and the mean morbidity was 10.3 ± 9.0 years. Compared to patients in the non-response group, those in the response group had a significantly lower RF titer (p = 0.04) and a significantly lower DAS28-ESR (3) (p < 0.01). In terms of components of the DAS 28-ESR (3), the number of tender joints (tender joint count) tender joint count and ESR were significantly different between the two groups (p < 0.05).
Clinical efficacy
Among the 67 patients, disease activity at week
Prediction analysis
To determine the predictors of response (DAS28-ESR (3) ≤ 3.2 at week 24), we used regression analysis to examine the relationship between the ΔDAS from baseline to week 4 (ΔDAS week 4) and the DAS28-ESR (3) at week 24 in the response group ( Table 4) . Among the patients who switched from TNFis, ΔDAS at week 4 could not predict the DA28-ESR (3) at week 24. On the other hand, ΔDAS at week 4 could predict the DA28-ESR (3) at week 24 in patients who switched from ABT. An ROC analysis showed that the best cutoff value for ΔDAS at week 4 to discriminate between the response and non-response groups was 0.74 (true-positive fraction, 1.0; false-positive fraction, 0.88; area under the curve, 0.98; 95% confidence interval [0.92-1.00], p < 0.01) (Figure 3 ).
Safety assessment
There were 144 AEs among the 67 patients. All AEs are shown in Table 5 . These AEs occurred throughout the course of TCZ therapy. Viral upper respiratory infection accounted for almost one-third of AEs. The rate of AEs in the patients who switched from TNFis and those who switched from ABT was not significantly different. Serious AEs, such as severe infections were observed in both treatment groups, and there was one patient with a malignant tumor in the TNFis group. The rate of AEs was comparable to those in previous reports 16, 17) . On average, TCZ was continued for 109 weeks. All patients survived during the study period.
Discussion
Among 67 patients treated with TCZ, we were able to show that 68% achieved low disease activity Some data are shown as mean ± SD. RF, rheumatoid factor; ACPA, Anti-cyclic citrullinated peptides antibody; MMP-3, matrix metalloproteinase-3; ESR, erythrocyte sedimentation rate; TJC, tender joint count; SJC, swelling joint count; CRP, C-reactive protein;
at week 24. RF titers before switching predicted disease activity at week 24 in the patients who switched from TNFis. ΔDAS at week 4 could predict disease activity at week 24 in the patients who switched from ABT. A total of 144 AEs were recorded during the safety assessment, resulting in a rate that was comparable to prior reports. These findings suggest that it is safe to switch to TCZ as a subsequent biologic. During our study, 68% of patients treated with TCZ as the subsequent biologic achieved low disease activity at week 24. In the ADACTA study, the rate of TCZtreated patients who achieved low disease activity at week 24 was 51.5%, and the remission rate was 39.9% 18) . Other studies showed remission rates that 24 Ando T Suzuki T et al Some data are shown as mean ± SD. *: p < 0.05 RF, rheumatoid factor; ACPA, Anti-cyclic citrullinated peptides antibody; MMP-3, matrix metalloproteinase-3; ESR, erythrocyte sedimentation rate; TJC, tender joint count; SJC, swelling joint count; CRP, C-reactive protein;
ranged from 34.1% to 43.9% 19, 20) at 24 weeks after initiating TCZ therapy. These results that are consistent with our own. A previous retrospective cohort study reported that the drug retention rate of TCZ as a subsequent biologic was significantly higher (94.7%) than that of TNFis (59.3%) 21) . Another study showed that the retention rate was higher for TCZ switched from a TNFi than for a TNFi switched from TCZ 3) . Thus in terms of retention rate, TCZ may be more suitable than TNFis as a subsequent biologic.
Few studies have examined the efficacy of switching from ABT to TCZ. During this study, 6 out of 14 patients who switched from ABT to TCZ achieved low disease activity at week 24. This result suggests the usefulness of treatment with TCZ after Some data are shown as mean ± SD. *: p < 0.05 RF, rheumatoid factor; ACPA, Anti-cyclic citrullinated peptides antibody; MMP-3, matrix metalloproteinase-3; ESR, erythrocyte sedimentation rate; TJC, tender joint count; SJC, swelling joint count; CRP, C-reactive protein;
ABT. A large retrospective cohort study reported that the retention rates for TCZ switched from ABT and for ABT switched from biologics other than TCZ were not significantly different 22) . Although the efficacy of TCZ as a subsequent biologic may be lower than that observed in treatment-naïve patients 16, 22, 23) , TCZ may be effective in patients who have received two or more biologics.
During our study, the ΔDAS at week 4 predicted the DAS28-ESR (3) at week 24 in patients switched from ABT, but not in those switched from a TNFi. We could not account for this difference. One potential explanation is the different mechanisms of action of these biologics. ABT affects CD80/86, a surface antigen on presenting cells required for T cell activation as the second signal. ABT may suppress ac- quired immunity, and predominantly T cell function, more than innate immunity. On the other hand, TCZ affects RA by inhibiting IL-6 receptor signaling. IL-6 plays a role in both acquired and innate immunity. Acquired immunity may contribute to the etiology of RA in some patients with an insufficient response to ABT more than innate immunity, and ABT might be appropriate in this population. A previous randomized prospective study reported that the clinical response at week 12 could predict low disease activity at 52 weeks in patients treated with certolizumab pegol 24) . Another prospec- tive study reported that RA patients who exhibited a good response at 1 month after starting TCZ were 5.5 times as likely to achieve remission at 36 months 23) . These reports support the theory that early treatment response can predict the achievement of low disease activity in RA patients. Our results showed that TCZ efficacy and predictors of TCZ response differed between patients switched from TNFis or ABT. Our results may support the hypothesis that the efficacy of biologics against RA varies according to the order of their use. A large-cohort (4970 patients), multicenter, retrospective study reported that the retention rate of biologics was higher in patients switched from a TNFi to TCZ than in those switched from TCZ to a TNFi 22) .
Based on these findings, the order of biologic administration may affect the efficacy of RA treatment. The reason for this is unknown, however, and larger studies and biochemical research are necessary to clarify the issue.
Although it is common for RA patients to switch biologics, there are few studies about switching between non-TNFis. Concomitant use of MTX is often avoided in the elderly due to reduced renal function and/or other complications. The large Japanese database NinJa showed that elderly RA patients were more commonly treated with non-TNFi monotherapy than younger patients 10) . Switching between ABT and TCZ is common in daily practice. Our study suggests that ΔDAS at week 4 can predict the achievement of low disease activity at week 24 in this situation. ABT tends to be used in elderly patients and/or those with comorbidities. Our findings are useful to aid the decision of whether to discontinue biologics soon after starting their administration and to avoid AEs associated with ineffective long-term use.
There are at least four limitations in this study. First, the study used a retrospective design, which is associated with certain inherent limitations. In this type of study, the analyzed data were not intended for use in a study; therefore, some data may be inaccurate and even unavailable. Second, the number of patients was small. Third, the standard tool to evaluate disease activity in RA patients is the DAS28-ESR. In this study, we did not have all of the necessary infor-mation to calculate DAS28-ESR, so we used the DAS28-ESR (3) instead. Although the ability to detect to symptomatic changes is similar when the DAS28 is calculated using 3 or 4 variables 25) , comparison between our study and previous studies may be difficult. Fourth, patients were excluded if the DAS28-ESR (3) could not be evaluated at weeks 0 and 24. Non-responders whose therapy was discontinued before week 24 may have been excluded. It is also possible that we overestimated the positive clinical response to TCZ.
Conclusion
Switching biologics from ABT to TCZ was as effective and safe as switching from a TNFi. ΔDAS at week 4 predicted the DAS28-ESR (3) at week 24 in patients who switched from ABT to TCZ, and this will help avoid AEs associated with ineffective longterm use. Switching from ABT to TCZ should be a beneficial strategy in RA.
